Central Trust Company’s Enanta Pharmaceuticals ENTA Stock Holding History

Central Trust Company’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-31	Closed	-$2K	–	1150
2019 Q4	$2K	Hold	31	–	–	﹤0.01%	1131
2019 Q3	$2K	Hold	31	–	–	﹤0.01%	1108
2019 Q2	$3K	Hold	31	–	–	﹤0.01%	1064
2019 Q1	$3K	Hold	31	–	–	﹤0.01%	1038
2018 Q4	$2K	Hold	31	–	–	﹤0.01%	1099
2018 Q3	$3K	Buy	+31	New	+$3.1K	﹤0.01%	1155

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Central Trust Company's ENTA Position: Q1 2020 in Review

Central Trust Company sold out of Enanta Pharmaceuticals (ENTA) in Q1 2020, closing a stake of 31 shares — an estimated $2K sold.

Central Trust Company first reported a position in ENTA in Q3 2018 and held it in 6 quarters. The position peaked at $3K in Q2 2019. 156 funds tracked by Wall St. Rank hold ENTA as of Q1 2020.

Central Trust Company reported no remaining Enanta Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Central Trust Company sold 31 Enanta Pharmaceuticals shares in Q1 2020, an estimated $2K.
Central Trust Company first reported a position in Enanta Pharmaceuticals in Q3 2018 and held it in 6 quarters.
Central Trust Company's Enanta Pharmaceuticals position peaked at $3K in Q2 2019.
156 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2020.

Based on Central Trust Company's 13F filing for Q1 2020, filed 17 Apr 2020.